DiaMedica Therapeutics Inc. (DMAC) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Minneapolis, MN, 美国. 现任CEO为 Dietrich John Pauls.
DMAC 拥有 IPO日期为 2012-08-03, 27 名全职员工, 在 NASDAQ Capital Marke, 市值为 $352.39M.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
